Microdosing GLP-1s: What the Trend Gets Wrong
Microdosing a GLP-1 has no trial evidence behind it. Why the escalation schedule exists, what the studies measured, and when a lower dose is legitimate.
Microdosing a GLP-1 has no trial evidence behind it. Why the escalation schedule exists, what the studies measured, and when a lower dose is legitimate.
Weight loss after 50 is harder because of muscle loss, lower activity and hormone shifts, not a broken metabolism. Here is what the evidence supports.
Many people on a GLP-1 want alcohol less. What the randomized trials actually show, where the evidence is thin, and why it is not an approved use.
The absolute contraindications to semaglutide and tirzepatide, the conditions that call for caution instead, and the red flags that mean call your clinician.
GLP-1 medications still work in perimenopause. What changes is muscle: the transition costs lean mass on its own, so protein and training come first.
A plateau on semaglutide or tirzepatide is expected physiology, not failure. Why it happens, when it arrives, and when it is worth investigating.
Protein first, fiber and fluids on purpose, and enough total food. What to eat on semaglutide or tirzepatide, plus the red flags that need a clinician.
The FDA ended routine compounding of semaglutide copies in 2025. What that means in Florida, the narrow exception left, and the risks worth knowing.
Three names that get used as if they were the same thing. What each one targets, which are FDA approved, and which is still investigational.
Three levers decide how much of your weight loss comes from fat: protein, resistance training, and how fast you push. The scale cannot tell you.
Mostly yes, and the trial data says so plainly. That is a fact about the condition rather than a failure of the drug or of you.
Most side effects come straight from how the drug works, arrive while the dose is rising, and are manageable. A few mean stop and call.